Everolimus-Loaded Reconstituted High-Density Lipoprotein Prepared by a Novel Dual Centrifugation Approach for Anti-Atherosclerotic Therapy
Benedikt Deuringer,Carmen Härdtner,Katja Krebs,Ralf Thomann,Martin Holzer,Ingo Hilgendorf,Regine Süss
DOI: https://doi.org/10.2147/IJN.S381483
IF: 7.033
2022-10-31
International Journal of Nanomedicine
Abstract:Benedikt Deuringer, 1 Carmen Härdtner, 2 Katja Krebs, 2 Ralf Thomann, 3 Martin Holzer, 1 Ingo Hilgendorf, 2, 4, &ast Regine Süss 1, &ast 1 Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, 79104, Germany; 2 Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, 79106, Germany; 3 FMF Materials Research Center, University of Freiburg, Freiburg, 79104, Germany; 4 Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg-Bad Krozingen and Faculty of Medicine, University of Freiburg, Freiburg, 79110, Germany &astThese authors contributed equally to this work Correspondence: Benedikt Deuringer, Pharmaceutical Technology and Biopharmacy, Sonnenstraße 5, Freiburg, 79104, Germany, Tel +49 761 203 6329, Fax +49 761 203 6326, Email Purpose: The conventional techniques for the preparation of reconstituted high-density lipoprotein (rHDL) are hampered by long process times, the need for large amounts of starting material, and harsh preparation conditions. Here, we present a novel rHDL preparation method to overcome these challenges. Furthermore, we propose a dual mode of action for rHDL loaded with the immunosuppressant drug everolimus (Eve-rHDL) in the context of atherosclerosis and cardiovascular disease. Methods: We use dual centrifugation for rHDL nanoparticle preparation and characterize the physicochemical properties by NS-TEM, N-PAGE, DLS, AF4, and HPLC. In addition, we determine the biological efficacy in human and murine cell culture with regard to cellular uptake, cholesterol efflux, and proliferation. Results: We confirm the characteristic particle size of 10 nm, discoidal morphology, and chemical composition of the rHDL preparations and identify dual centrifugation as an ideal method for cost-effective aseptic rHDL manufacturing. rHDL can be prepared in approx. 1.5 h with batch sizes as little as 89 μL. Moreover, we demonstrate the cholesterol efflux capacity and anti-proliferative activity of Eve-rHDL in vitro. The anti-proliferative effects were comparable to free Eve, thus confirming the suitability of rHDL as a capable drug delivery vehicle. Conclusion: Eve-rHDL shows great efficacy in vitro and may further be employed to target atherosclerotic plaques in vivo. Highly effective anti-atherosclerotic therapy might be feasible by reducing both inflammatory- and lipid burden of the plaques. Dual centrifugation is an ideal technique for the efficient application of the rHDL platform in cardiovascular disease and beyond. Keywords: atherosclerosis, cholesterol efflux, drug delivery, everolimus, proliferation, protein-conjugate Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. One of the underlying principles of CVD is the process of atherogenesis, which is associated with a retention of cholesterol-containing low-density lipoprotein in the intima layer of arteries and an inflammatory response. 1 Standard treatment regimens comprise lifestyle management, control of vascular inflammation, and lipoprotein modification. 2–4 High-density lipoprotein (HDL) can be employed to stabilize atherosclerotic plaques by the reverse cholesterol transport (RCT) mechanism. Cholesterol-efflux from foam cell macrophages is mediated by the interaction of HDL with cellular receptors such as scavenger receptor B1 and ATP-binding cassette transporters A1 and G1. 5 The development of HDL-mimicking nanoparticles, ie, reconstituted HDL (rHDL), is therefore a promising option for plaque modification and the reduction of atherosclerotic burden. 6 Small, discoidal rHDL is an 8 to 12 nm sized particle consisting of lipids and amphiphilic proteins such as apolipoprotein A1 (ApoA1). The proteins circumscribe the perimeter of the rHDL nanodiscs and stabilize the lipids in a planar bilayer. 7 Due to the large capacity for hydrophobic cargo, rHDL can be exploited as a capable delivery vehicle for hydrophobic active pharmaceutical ingredients (APIs), which offers significant benefits in comparison to other delivery systems such as liposomes or polymeric nanoparticles. As rHDL resembles endogenous HDL, it can escape elimination by the mononuclear phagocytic system and protect incorporated APIs from degradation. Due to the extremely small size, the nanoparticles can accumulate in leaky microvasculature, congruent with the enhanced permeability and retention effect. Moreover, rHDL possesses an intrinsic targeting effect to athero -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology